{"id":5680,"date":"2005-07-06T10:03:00","date_gmt":"2005-07-06T10:03:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=5680"},"modified":"2021-07-09T11:07:10","modified_gmt":"2021-07-09T11:07:10","slug":"immunomodulatory-effects-of-selective-leucocytapheresis-as-a-new-adjunct-to-interferon-alpha2b-plus-ribavirin-combination-therapy-a-prospective-study-in-patients-with-high-plasma-hcv-viraemia","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/immunomodulatory-effects-of-selective-leucocytapheresis-as-a-new-adjunct-to-interferon-alpha2b-plus-ribavirin-combination-therapy-a-prospective-study-in-patients-with-high-plasma-hcv-viraemia\/","title":{"rendered":"Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon-alpha2b plus ribavirin combination therapy: a prospective study in patients with high plasma HCV viraemia"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Sawada+K&amp;cauthor_id=15850468\">K Sawada<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15850468\/#affiliation-1\">1<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Masaki+N&amp;cauthor_id=15850468\">N Masaki<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Hayashi+S&amp;cauthor_id=15850468\">S Hayashi<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Zeniya+M&amp;cauthor_id=15850468\">M Zeniya<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ishikawa+T&amp;cauthor_id=15850468\">T Ishikawa<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Takahashi+H&amp;cauthor_id=15850468\">H Takahashi<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ohnishi+K&amp;cauthor_id=15850468\">K Ohnishi<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Fukunaga+K&amp;cauthor_id=15850468\">K Fukunaga<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Hara+N&amp;cauthor_id=15850468\">N Hara<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Yamamoto+T&amp;cauthor_id=15850468\">T Yamamoto<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Hada+T&amp;cauthor_id=15850468\">T Hada<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Toda+G&amp;cauthor_id=15850468\">G Toda<\/a>, J Viral Hepat. 2005 May;12(3):274-82.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>In conclusion, enhanced efficacy of IFN\/RBV following GMA might be attributed to a more efficient immune function and a renewed IFN signaling towards HCV.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15850468\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/15850468\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>K Sawada&nbsp;1,&nbsp;N Masaki,&nbsp;S Hayashi,&nbsp;M Zeniya,&nbsp;T Ishikawa,&nbsp;H Takahashi,&nbsp;K Ohnishi,&nbsp;K Fukunaga,&nbsp;N Hara,&nbsp;T Yamamoto,&nbsp;T Hada,&nbsp;G Toda, J Viral Hepat. 2005 May;12(3):274-82. In conclusion, enhanced efficacy of IFN\/RBV following GMA might be attributed to a more efficient immune function and a renewed IFN signaling towards HCV. https:\/\/pubmed.ncbi.nlm.nih.gov\/15850468\/<\/p>\n","protected":false},"template":"","scientific_tags":[402,330,303,314,403],"class_list":["post-5680","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-aribavirin","scientific_tags-clinical-trial","scientific_tags-combination","scientific_tags-digestive","scientific_tags-interferon"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon-alpha2b plus ribavirin combination therapy: a prospective study in patients with high plasma HCV viraemia - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-effects-of-selective-leucocytapheresis-as-a-new-adjunct-to-interferon-alpha2b-plus-ribavirin-combination-therapy-a-prospective-study-in-patients-with-high-plasma-hcv-viraemia\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon-alpha2b plus ribavirin combination therapy: a prospective study in patients with high plasma HCV viraemia - Adacyte\" \/>\n<meta property=\"og:description\" content=\"K Sawada&nbsp;1,&nbsp;N Masaki,&nbsp;S Hayashi,&nbsp;M Zeniya,&nbsp;T Ishikawa,&nbsp;H Takahashi,&nbsp;K Ohnishi,&nbsp;K Fukunaga,&nbsp;N Hara,&nbsp;T Yamamoto,&nbsp;T Hada,&nbsp;G Toda, J Viral Hepat. 2005 May;12(3):274-82. In conclusion, enhanced efficacy of IFN\/RBV following GMA might be attributed to a more efficient immune function and a renewed IFN signaling towards HCV. https:\/\/pubmed.ncbi.nlm.nih.gov\/15850468\/\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-effects-of-selective-leucocytapheresis-as-a-new-adjunct-to-interferon-alpha2b-plus-ribavirin-combination-therapy-a-prospective-study-in-patients-with-high-plasma-hcv-viraemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-09T11:07:10+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-effects-of-selective-leucocytapheresis-as-a-new-adjunct-to-interferon-alpha2b-plus-ribavirin-combination-therapy-a-prospective-study-in-patients-with-high-plasma-hcv-viraemia\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-effects-of-selective-leucocytapheresis-as-a-new-adjunct-to-interferon-alpha2b-plus-ribavirin-combination-therapy-a-prospective-study-in-patients-with-high-plasma-hcv-viraemia\/\",\"name\":\"Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon-alpha2b plus ribavirin combination therapy: a prospective study in patients with high plasma HCV viraemia - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2005-07-06T10:03:00+00:00\",\"dateModified\":\"2021-07-09T11:07:10+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-effects-of-selective-leucocytapheresis-as-a-new-adjunct-to-interferon-alpha2b-plus-ribavirin-combination-therapy-a-prospective-study-in-patients-with-high-plasma-hcv-viraemia\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon-alpha2b plus ribavirin combination therapy: a prospective study in patients with high plasma HCV viraemia - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-effects-of-selective-leucocytapheresis-as-a-new-adjunct-to-interferon-alpha2b-plus-ribavirin-combination-therapy-a-prospective-study-in-patients-with-high-plasma-hcv-viraemia\/","og_locale":"fr_FR","og_type":"article","og_title":"Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon-alpha2b plus ribavirin combination therapy: a prospective study in patients with high plasma HCV viraemia - Adacyte","og_description":"K Sawada&nbsp;1,&nbsp;N Masaki,&nbsp;S Hayashi,&nbsp;M Zeniya,&nbsp;T Ishikawa,&nbsp;H Takahashi,&nbsp;K Ohnishi,&nbsp;K Fukunaga,&nbsp;N Hara,&nbsp;T Yamamoto,&nbsp;T Hada,&nbsp;G Toda, J Viral Hepat. 2005 May;12(3):274-82. In conclusion, enhanced efficacy of IFN\/RBV following GMA might be attributed to a more efficient immune function and a renewed IFN signaling towards HCV. https:\/\/pubmed.ncbi.nlm.nih.gov\/15850468\/","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-effects-of-selective-leucocytapheresis-as-a-new-adjunct-to-interferon-alpha2b-plus-ribavirin-combination-therapy-a-prospective-study-in-patients-with-high-plasma-hcv-viraemia\/","og_site_name":"Adacyte","article_modified_time":"2021-07-09T11:07:10+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-effects-of-selective-leucocytapheresis-as-a-new-adjunct-to-interferon-alpha2b-plus-ribavirin-combination-therapy-a-prospective-study-in-patients-with-high-plasma-hcv-viraemia\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-effects-of-selective-leucocytapheresis-as-a-new-adjunct-to-interferon-alpha2b-plus-ribavirin-combination-therapy-a-prospective-study-in-patients-with-high-plasma-hcv-viraemia\/","name":"Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon-alpha2b plus ribavirin combination therapy: a prospective study in patients with high plasma HCV viraemia - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2005-07-06T10:03:00+00:00","dateModified":"2021-07-09T11:07:10+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/immunomodulatory-effects-of-selective-leucocytapheresis-as-a-new-adjunct-to-interferon-alpha2b-plus-ribavirin-combination-therapy-a-prospective-study-in-patients-with-high-plasma-hcv-viraemia\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/5680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=5680"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=5680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}